VIMRxyn synthetic hypericin data

VMRX (Stamford, Conn.) announced Phase I safety results with intravenous dosing in 27 patients with CD4 cell counts below 300, most of whom were positive for the p24 serum marker.

A 25 percent increase of at least 50 CD4 cells was found in two of 20 patients, with trends to a decrease in p24 levels and in viral cultures in peripheral blood mononuclear cells. ...